Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18]fluorodeoxyglucose positron emission tomography

Val J. Lowe, Frank R. Dunphy, Mark Varvares, Han Kim, Mark Wittry, Cherie H. Dunphy, Theresa Dunleavy, Erin McDonough, Jeffrey Minster, James Fletcher, James H. Boyd

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

Background. [F-18]Fluorodeoxyglucose (FDG)-position emission tomography (PET) can measure the metabolic activity of tissues; FDG-PET may be able to predict response to chemotherapy by identifying changes in tumor metabolism. Measurement of response to treatment may help improve survival in the management of advanced head and neck cancer. We evaluated this particular use of FDG-PET in patients participating in a neoadjuvant organ-preservation protocol using taxol and carboplatin and compared pathologic response after chemotherapy with changes in tumor metabolism measured by FDG-PET. Methods. Serial FDG-PET studies (n = 56) were performed in patients (n = 28) with stage III/IV head and neck cancer participating in a neoadjuvant organ- preservation protocol. The FDG-PET studies were performed before and after chemotherapy. All patients had tissue biopsies before and after chemotherapy. Patients were classified as pathologic complete response (PCR) or residual disease (RD) based on tissue biopsies. Visual analysis of PET scans was performed to identify patients with complete response by PET, and these findings were compared with pathology results. Metabolic changes were also evaluated using standardized uptake ratios (SUR) of FDG. Results. The sensitivity and specificity of PET for residual cancer after therapy was 90% (19/21) and 83% (5/6), respectively. Two patients had initially negative biopsies and positive PET studies for persistent disease. Pathology review and rebiospy led to confirmation of the PET results in these cases, giving a sensitivity of 90% for initial tissue biopsy. Conclusions. In this preliminary analysis, FDG-PET was accurate in classifying response to chemotherapy in most patients. Fluorodeoxyglucose-PET may identify residual viable tumor when it is otherwise undetectable.

Original languageEnglish (US)
Pages (from-to)666-674
Number of pages9
JournalHead and Neck
Volume19
Issue number8
DOIs
StatePublished - Dec 1997
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Head and Neck Neoplasms
Positron-Emission Tomography
Tomography
Drug Therapy
Organ Preservation
Biopsy
Residual Neoplasm
Pathology
Carboplatin
Paclitaxel
Neoplasms

Keywords

  • Chemotherapy
  • F-18 fluorodeoxyglucose (FDG)
  • Head and neck neoplasms
  • Positron emission tomography
  • Treatment monitoring

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18]fluorodeoxyglucose positron emission tomography. / Lowe, Val J.; Dunphy, Frank R.; Varvares, Mark; Kim, Han; Wittry, Mark; Dunphy, Cherie H.; Dunleavy, Theresa; McDonough, Erin; Minster, Jeffrey; Fletcher, James; Boyd, James H.

In: Head and Neck, Vol. 19, No. 8, 12.1997, p. 666-674.

Research output: Contribution to journalArticle

Lowe, Val J. ; Dunphy, Frank R. ; Varvares, Mark ; Kim, Han ; Wittry, Mark ; Dunphy, Cherie H. ; Dunleavy, Theresa ; McDonough, Erin ; Minster, Jeffrey ; Fletcher, James ; Boyd, James H. / Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18]fluorodeoxyglucose positron emission tomography. In: Head and Neck. 1997 ; Vol. 19, No. 8. pp. 666-674.
@article{0468aad47af749008251ed3e2ab5daf1,
title = "Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18]fluorodeoxyglucose positron emission tomography",
abstract = "Background. [F-18]Fluorodeoxyglucose (FDG)-position emission tomography (PET) can measure the metabolic activity of tissues; FDG-PET may be able to predict response to chemotherapy by identifying changes in tumor metabolism. Measurement of response to treatment may help improve survival in the management of advanced head and neck cancer. We evaluated this particular use of FDG-PET in patients participating in a neoadjuvant organ-preservation protocol using taxol and carboplatin and compared pathologic response after chemotherapy with changes in tumor metabolism measured by FDG-PET. Methods. Serial FDG-PET studies (n = 56) were performed in patients (n = 28) with stage III/IV head and neck cancer participating in a neoadjuvant organ- preservation protocol. The FDG-PET studies were performed before and after chemotherapy. All patients had tissue biopsies before and after chemotherapy. Patients were classified as pathologic complete response (PCR) or residual disease (RD) based on tissue biopsies. Visual analysis of PET scans was performed to identify patients with complete response by PET, and these findings were compared with pathology results. Metabolic changes were also evaluated using standardized uptake ratios (SUR) of FDG. Results. The sensitivity and specificity of PET for residual cancer after therapy was 90{\%} (19/21) and 83{\%} (5/6), respectively. Two patients had initially negative biopsies and positive PET studies for persistent disease. Pathology review and rebiospy led to confirmation of the PET results in these cases, giving a sensitivity of 90{\%} for initial tissue biopsy. Conclusions. In this preliminary analysis, FDG-PET was accurate in classifying response to chemotherapy in most patients. Fluorodeoxyglucose-PET may identify residual viable tumor when it is otherwise undetectable.",
keywords = "Chemotherapy, F-18 fluorodeoxyglucose (FDG), Head and neck neoplasms, Positron emission tomography, Treatment monitoring",
author = "Lowe, {Val J.} and Dunphy, {Frank R.} and Mark Varvares and Han Kim and Mark Wittry and Dunphy, {Cherie H.} and Theresa Dunleavy and Erin McDonough and Jeffrey Minster and James Fletcher and Boyd, {James H.}",
year = "1997",
month = "12",
doi = "10.1002/(SICI)1097-0347(199712)19:8<666::AID-HED4>3.0.CO;2-3",
language = "English (US)",
volume = "19",
pages = "666--674",
journal = "Head and Neck Surgery",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18]fluorodeoxyglucose positron emission tomography

AU - Lowe, Val J.

AU - Dunphy, Frank R.

AU - Varvares, Mark

AU - Kim, Han

AU - Wittry, Mark

AU - Dunphy, Cherie H.

AU - Dunleavy, Theresa

AU - McDonough, Erin

AU - Minster, Jeffrey

AU - Fletcher, James

AU - Boyd, James H.

PY - 1997/12

Y1 - 1997/12

N2 - Background. [F-18]Fluorodeoxyglucose (FDG)-position emission tomography (PET) can measure the metabolic activity of tissues; FDG-PET may be able to predict response to chemotherapy by identifying changes in tumor metabolism. Measurement of response to treatment may help improve survival in the management of advanced head and neck cancer. We evaluated this particular use of FDG-PET in patients participating in a neoadjuvant organ-preservation protocol using taxol and carboplatin and compared pathologic response after chemotherapy with changes in tumor metabolism measured by FDG-PET. Methods. Serial FDG-PET studies (n = 56) were performed in patients (n = 28) with stage III/IV head and neck cancer participating in a neoadjuvant organ- preservation protocol. The FDG-PET studies were performed before and after chemotherapy. All patients had tissue biopsies before and after chemotherapy. Patients were classified as pathologic complete response (PCR) or residual disease (RD) based on tissue biopsies. Visual analysis of PET scans was performed to identify patients with complete response by PET, and these findings were compared with pathology results. Metabolic changes were also evaluated using standardized uptake ratios (SUR) of FDG. Results. The sensitivity and specificity of PET for residual cancer after therapy was 90% (19/21) and 83% (5/6), respectively. Two patients had initially negative biopsies and positive PET studies for persistent disease. Pathology review and rebiospy led to confirmation of the PET results in these cases, giving a sensitivity of 90% for initial tissue biopsy. Conclusions. In this preliminary analysis, FDG-PET was accurate in classifying response to chemotherapy in most patients. Fluorodeoxyglucose-PET may identify residual viable tumor when it is otherwise undetectable.

AB - Background. [F-18]Fluorodeoxyglucose (FDG)-position emission tomography (PET) can measure the metabolic activity of tissues; FDG-PET may be able to predict response to chemotherapy by identifying changes in tumor metabolism. Measurement of response to treatment may help improve survival in the management of advanced head and neck cancer. We evaluated this particular use of FDG-PET in patients participating in a neoadjuvant organ-preservation protocol using taxol and carboplatin and compared pathologic response after chemotherapy with changes in tumor metabolism measured by FDG-PET. Methods. Serial FDG-PET studies (n = 56) were performed in patients (n = 28) with stage III/IV head and neck cancer participating in a neoadjuvant organ- preservation protocol. The FDG-PET studies were performed before and after chemotherapy. All patients had tissue biopsies before and after chemotherapy. Patients were classified as pathologic complete response (PCR) or residual disease (RD) based on tissue biopsies. Visual analysis of PET scans was performed to identify patients with complete response by PET, and these findings were compared with pathology results. Metabolic changes were also evaluated using standardized uptake ratios (SUR) of FDG. Results. The sensitivity and specificity of PET for residual cancer after therapy was 90% (19/21) and 83% (5/6), respectively. Two patients had initially negative biopsies and positive PET studies for persistent disease. Pathology review and rebiospy led to confirmation of the PET results in these cases, giving a sensitivity of 90% for initial tissue biopsy. Conclusions. In this preliminary analysis, FDG-PET was accurate in classifying response to chemotherapy in most patients. Fluorodeoxyglucose-PET may identify residual viable tumor when it is otherwise undetectable.

KW - Chemotherapy

KW - F-18 fluorodeoxyglucose (FDG)

KW - Head and neck neoplasms

KW - Positron emission tomography

KW - Treatment monitoring

UR - http://www.scopus.com/inward/record.url?scp=0030658952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030658952&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0347(199712)19:8<666::AID-HED4>3.0.CO;2-3

DO - 10.1002/(SICI)1097-0347(199712)19:8<666::AID-HED4>3.0.CO;2-3

M3 - Article

C2 - 9406745

AN - SCOPUS:0030658952

VL - 19

SP - 666

EP - 674

JO - Head and Neck Surgery

JF - Head and Neck Surgery

SN - 1043-3074

IS - 8

ER -